Diaceutics Regulatory News (DXRX)

Diaceutics PLC

("Diaceutics" or the "Company" or the "Group")

Directorate change

Diaceutics PLC (AIM: DXRX), announces the resignation of Julie Goonewardene as Non-Executive Chair. Julie will step down on 31 December 2020. Having been with Diaceutics for almost 10 years Julie has, with the support of the Board, decided to step down.

Julie Goonewardene commented: "It has been my pleasure and privilege to work with the Diaceutics team for the better part of a decade. I have enjoyed the journey of helping guide the Company from a small Irish boutique consultancy to a global publicly traded data enabled platform firm. My goal has always been to see the Company reach the important milestone of launching its transformative platform, DXRX, and together we have achieved this objective. DXRX has great potential and I look forward to seeing how it transforms the diagnostics industry."

Peter Keeling, Chief Executive Officer of Diaceutics said: "Julie has been a trusted partner and friend through all of the growth stages of the Company and a key contributor to our most successful strategies right up to the successful IPO in March 2019.  On behalf of the Board, we would like to thank Julie for all her hard work and the support she has given us during her time with Diaceutics. She has been a valued member of the Group, and we are sad to see her go."

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - a proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company, listed on the AIM Market of the London Stock Exchange, has created commercially useful data sets for every precision medicine that has come to market. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries. www.diaceutics.com